Two funds each report 2.2% of Monte Rosa Therapeutics (GLUE), with one manager reporting both holdings.
An SEC filing reveals that TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., along with their general partners, each beneficially own 1,890,766 shares of Monte Rosa Therapeutics (GLUE), representing 2.2% of the class. Chen Yu, as the sole managing member of both general partners, reports a combined beneficial ownership of 3,781,532 shares, or 4.4%. These percentages are based on 85,450,119 shares outstanding as of October 30, 2026.
T. Rowe Price reports 7.36 million shares in Monte Rosa Therapeutics (GLUE).
T. Rowe Price Associates, Inc. has reported an 8.6% stake in Monte Rosa Therapeutics, Inc. (GLUE), amounting to 7,356,865 common shares. This information comes from an Amendment No. 8 to a SCHEDULE 13G/A SEC filing. T. Rowe Price stated it has sole voting power over 7,349,108 shares and sole dispositive power over 7,356,865 shares, though it explicitly denied that the report signifies an admission of beneficial ownership.
Monte Rosa Therapeutics (GLUE) Stock Fair Value Edges Lower As Analysts Weigh NEK7 Promise And Risk
The blended fair value estimate for Monte Rosa Therapeutics (GLUE) has decreased from US$28.00 to US$25.38, influenced by analyst optimism regarding the MRT-8102 and NEK7 programs, coupled with concerns over execution risk and current valuation. Analysts from UBS and H.C. Wainwright initiated coverage with "Buy" ratings, highlighting the potential of MRT-8102 for chronic inflammatory diseases and a robust pipeline. Conversely, Jefferies cut its price target, emphasizing increased operational and clinical delivery risk for the NEK7 Phase 2 program and sensitivity to valuation given recent Q3 updates.
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
Monte Rosa Therapeutics presented preclinical data at ACR Convergence 2026 for MRT-8102, a NEK7-directed molecular glue degrader, demonstrating its potential in treating gout. The data showed MRT-8102 inhibited NLRP3 inflammasome activity in human experimental systems and reduced inflammation in a rabbit model of gouty arthritis. The company plans to initiate a Phase 2 GEMINI-1 study in Q4 2026, with initial data expected in H2 2027, to evaluate the prevention of recurrent flares in gout patients.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Has Consensus Target Price of $26.44
Monte Rosa Therapeutics (NASDAQ:GLUE) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $26.44. The company recently reported better-than-expected quarterly EPS of $0.03 and revenue of $54.37 million, significantly surpassing analyst estimates. Despite remaining unprofitable with a negative net margin, institutional investors hold a substantial 79.96% stake in the company.
Monte Rosa Therapeutics, Inc. (GLUE) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Monte Rosa Therapeutics, Inc. (GLUE), displaying average monthly price returns from 2021 to 2026. As of November 6, the stock closed at $10.57, up 3.12%, and showed further gains in pre-market trading. The page also includes various market data and links to company-specific information.
Monte Rosa Therapeutics (NASDAQ:GLUE) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen has upgraded Monte Rosa Therapeutics (NASDAQ:GLUE) from a "sell" to a "hold" rating, contributing to a "Moderate Buy" consensus among analysts with an average price target of $26.44. The company recently surpassed quarterly earnings estimates, reporting an EPS of $0.03 against an expected loss of $0.21, and revenues of $54.37 million exceeding forecasts of $33.87 million. Despite some institutional investors increasing their stakes, 79.96% of the stock is held by hedge funds and other institutional investors.
Monte Rosa Therapeutics earnings beat by $0.19, revenue topped estimates
Monte Rosa Therapeutics (NASDAQ: GLUE) reported a strong third quarter, beating analyst estimates with an EPS of $-0.05, significantly better than the $-0.24 anticipated. The company also surpassed revenue expectations, bringing in $50M against a consensus estimate of $31.47M. Despite these positive results, the company's stock has seen a decline of -31.86% over the last 3 months and -20.68% over the last 12 months.
A $50M Novartis milestone enters Q3 revenue as Monte Rosa (GLUE) reverses its loss.
Monte Rosa Therapeutics (GLUE) reported a significant swing to a $3.1 million Q3 profit, largely driven by a $50 million milestone payment from Novartis. This payment was triggered by the first patient visit in a Phase 2 Sjögren's disease study of MRT-6160. The company also announced positive topline results from its Phase 1 study of MRT-8102 and expects to initiate further Phase 2b and Phase 2 studies in coronary artery disease, gout, and psoriatic arthritis.
Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics announced the grant of inducement equity awards to four new non-executive employees. These awards, consisting of non-qualified stock options and restricted stock units, were granted outside of stockholder-approved plans and are a material inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The company is a clinical-stage biotechnology firm focused on developing molecular glue degrader medicines for various serious diseases.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics, Inc. announced its management will participate in several upcoming investor conferences in November and December 2026, including Guggenheim's Healthcare Innovation Conference, UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and Piper Sandler's Healthcare Conference. Webcasts of these fireside chats will be available on the company's investor relations website. Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing molecular glue degrader medicines.
Four fireside chats are scheduled in Boston, London and New York.
Monte Rosa Therapeutics (GLUE) management will participate in four investor conference fireside chats in November and December 2026. These include Guggenheim's 3rd Annual Healthcare Innovation Conference in Boston, UBS Global Biopharma Conference in London, Jefferies Global Healthcare Conference in London, and Piper Sandler 38th Annual Healthcare Conference in New York. Webcasts of these events will be available on the company's website.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics, a clinical-stage biotechnology company, announced its participation in four upcoming investor conferences in November and December 2026. Management will hold fireside chats at Guggenheim's Healthcare Innovation Conference, UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and Piper Sandler's Annual Healthcare Conference. Webcasts of these events will be available on the company's website.
Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics (Nasdaq: GLUE) announced the grant of inducement equity awards to four newly hired non-executive employees, effective November 2, 2026. These awards include options to purchase 33,775 shares at an exercise price of $10.63 per share and restricted stock units for 7,400 shares, both vesting over four years subject to continued service. The awards were approved by the compensation committee under the 2026 Inducement Plan as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics, a clinical-stage biotechnology company, announced its management will participate in several upcoming investor conferences in November and December 2026. These include Guggenheim's 3rd Annual Healthcare Innovation Conference, UBS Global Biopharma Conference 2026, Jefferies Global Healthcare Conference, and Piper Sandler 38th Annual Healthcare Conference, where they will hold fireside chats. Webcasts of these events will be available on the company's investor relations website.
Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Monte Rosa Therapeutics (GLUE) is anticipated to report a year-over-year increase in earnings on higher revenues for the quarter ended September 2026, though analysts expect a quarterly loss of $0.10 per share. The consensus EPS estimate has been revised significantly lower by 42.93% over the last 30 days, and the company's Earnings ESP of -361.54% combined with a Zacks Rank #2 makes it difficult to predict an earnings beat. Historically, Monte Rosa Therapeutics has only surpassed EPS estimates once in the last four quarters.
Monte Rosa Therapeutics (GLUE) Set to Announce Quarterly Earnings on Thursday
Monte Rosa Therapeutics (GLUE) is slated to announce its Q3 2026 earnings before market open on Thursday, November 5th. Analysts anticipate a loss of $0.2396 per share and revenue of $33.87 million, with the earnings call scheduled for November 6th. The company missed expectations in the prior quarter, reporting a larger-than-expected loss and lower revenue.
Monte Rosa Therapeutics Announces Novartis Initiates Phase 2 Study of MRT-6160 in Psoriatic Arthritis
Monte Rosa Therapeutics announced that its partner Novartis has initiated a second Phase 2 clinical study for MRT-6160 (DDY391), a VAV1-directed molecular glue degrader, in patients with active moderate to severe psoriatic arthritis. This development triggers a $37.5 million milestone payment to Monte Rosa from Novartis upon the first patient visit. The study, designed as a randomized, double-blind, placebo-controlled trial, aims to evaluate the safety and efficacy of MRT-6160, which has previously shown promise in immune-mediated diseases.
Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?
Options traders are showing significant interest in Monte Rosa Therapeutics (GLUE) stock, indicated by the high implied volatility of its December 18, 2026 $20.00 Call options. This suggests expectations of a substantial price movement, possibly due to an upcoming event. Despite the options market's anticipation, analysts currently rate Monte Rosa Therapeutics as a Zacks Rank #4 (Sell), although recent earnings estimates have improved.
Monte Rosa Therapeutics, Inc. Estimates – NASDAQ:GLUE
This article provides an overview of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) financial data and analyst estimates on TradingView. It directs users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements. The content emphasizes that it is not investment advice and encourages users to conduct their own research.
189,430 Shares in Monte Rosa Therapeutics, Inc. $GLUE Purchased by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. acquired 189,430 shares of Monte Rosa Therapeutics (NASDAQ:GLUE) during the third quarter, valued at approximately $2.26 million, giving them a 0.22% stake. Despite Monte Rosa Therapeutics missing recent quarterly earnings and revenue expectations, analysts maintain a "Moderate Buy" consensus rating with an average price target of $26.67, supported by the company's molecular glue degrader drug-development platform. Institutional investors now collectively own nearly 80% of GLUE stock.
UBS upgrades Monte Rosa Therapeutics stock to Hold while trials advance
UBS has upgraded Monte Rosa Therapeutics (GLUE) stock to Hold after the company reported positive Phase 1 trial results for MRT-8102, showing an 85% reduction in hsCRP. The biotech firm also advanced MRT-6160 to Phase 2. Despite a challenging financial profile with a Q2 2026 net loss of $43.40 million, future clinical milestones for gout, coronary artery disease, and hidradenitis suppurativa are anticipated in late 2026 and early 2027.
Monte Rosa Therapeutics (NASDAQ:GLUE) Raised to Hold at UBS Group
UBS Group upgraded Monte Rosa Therapeutics (NASDAQ:GLUE) to a "Hold" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $26.67. The company's shares opened at $9.89, having dropped 6% and are near their 52-week low. Monte Rosa Therapeutics reported a quarterly loss of $0.43 per share and revenue of $8.97 million, both missing analyst expectations.
UBS raises target for Monte Rosa stock from USD 17 to USD 19
UBS has increased its price target for Monte Rosa Therapeutics (GLUE) from $17.00 to $19.00, maintaining a Buy rating. This adjustment follows the company's Q2 2026 revenue of $8.97 million and a GAAP net loss of $43.40 million. Monte Rosa is also advancing several clinical studies, with key data and study initiations expected in late 2026 and early 2027.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Rated "Moderate Buy" by Sell-Side Brokerages
Monte Rosa Therapeutics (NASDAQ:GLUE) has received a "Moderate Buy" consensus rating from twelve analysts, with an average 12-month price target of $26.67, significantly higher than its current share price of $10.52. Despite this positive analyst outlook, the clinical-stage biotech company recently reported weaker-than-expected quarterly results, missing both adjusted loss per share and revenue estimates. Institutional investors hold a substantial 79.96% stake in the company, with notable new positions and increased holdings by firms like Opaleye Management and Squarepoint Ops.
UBS Adjusts Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Buy Rating
UBS has increased its price target for Monte Rosa Therapeutics (NASDAQ: GLUE) to $19 from $17, while reiterating a Buy rating on the stock. This adjustment suggests a positive outlook from the financial institution regarding the company's future performance.
Monte Rosa Therapeutics (NasdaqGS:GLUE) Stock Forecast & Analyst Predictions
Monte Rosa Therapeutics (GLUE) is forecast to experience declining earnings but growing annual revenue. The company recently announced positive Phase 1 data for MRT-8102 in inflammatory conditions and initiated Phase 2 studies for MRT-8102, MRT-6160 (partnered with Novartis), and MRT-2359. Analyst sentiment varies, with some upgrading revenue forecasts and highlighting the company's strong cash position, while others note volatility and insider selling.
Monte Rosa Therapeutics Price Target Raised to $19.00/Share From $17.00 by UBS
UBS has increased its price target for Monte Rosa Therapeutics (NASDAQ:GLUE) shares to $19.00, up from the previous target of $17.00. This adjustment reflects an updated outlook from the firm regarding the company's valuation.
Monte Rosa Therapeutics Inc (GLUE-Q) Stock Price and News
This article provides stock price information and recent news for Monte Rosa Therapeutics Inc. (GLUE-Q), a biotechnology company focused on developing precision medicines. It highlights analyst ratings, pipeline updates such as positive Phase 1 data for MRT-8102 and MRT-6160 entering Phase 2, and investor conference participation.
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
Monte Rosa Therapeutics announced positive results from its Phase I GFORCE-1 study of MRT-8102, showing significant NEK7 degradation and reductions in inflammatory biomarkers with a safety profile comparable to placebo. The company plans to advance MRT-8102 into a Phase IIb cardiovascular study (GFORCE-2) in early 2027, along with Phase II trials for gout and hidradenitis suppurativa. While biomarker data are promising, further studies are needed to confirm the impact on major adverse cardiovascular events.
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
Monte Rosa Therapeutics announced it will host a conference call and webcast on October 1, 2026, to present results from its GFORCE-1 Phase 1 study of MRT-8102. The study evaluated the NEK7-directed molecular glue degrader MRT-8102 in subjects with elevated cardiovascular disease risk, focusing on safety, activity data across multiple dose levels, and its modulation of atherosclerotic cardiovascular disease drivers. Monte Rosa Therapeutics is a clinical-stage biotechnology company specializing in molecular glue degrader medicines for serious diseases.
Monte Rosa Therapeutics (GLUE) Following Phase 1 Data Faces A Big Fair Value Question
Monte Rosa Therapeutics (GLUE) is gaining attention after releasing Phase 1 GFORCE-1 data for MRT-8102, a NEK7-directed degrader. Despite recent share price weakness, its long-term performance remains strong, with a valuation narrative suggesting it's 62% undervalued with a fair value of $28. However, concerns about its high P/S ratio and potential risks to timelines and revenue projections mean investors need to carefully weigh the mixed messages on valuation and risk.
HC Wainwright & Co. reiterates Buy rating on Monte Rosa Therapeutics, $25 price target
HC Wainwright & Co. has reiterated a Buy rating for Monte Rosa Therapeutics (GLUE) with a price target of $25.00, suggesting a significant upside of 138.1% from its recent closing price. This positive outlook is supported by the company's strong pipeline of clinical programs targeting immune-mediated diseases and metastatic prostate cancer, and a robust probability-adjusted valuation of approximately $2.9 billion.
Brokers Set Expectations for GLUE Q3 Earnings
HC Wainwright anticipates Monte Rosa Therapeutics (NASDAQ:GLUE) to report a Q3 2026 loss of $0.45 per share, maintaining a "Strong Buy" rating despite the company missing previous earnings and revenue expectations. Analysts generally hold a "Moderate Buy" consensus with an average price target of $28, significantly higher than its current share price of $10.50. The article highlights positive sentiment due to encouraging Phase 1 data for MRT-8102 and pipeline advancement, tempered by neutral sentiment regarding employee equity grants.
H.C. Wainwright Initiates Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Announces Target Price $25
H.C. Wainwright has initiated coverage on Monte Rosa Therapeutics (GLUE.US) with a Buy rating. The firm has set a price target of $25 for the company's stock. This indicates a positive outlook from the analyst firm regarding Monte Rosa Therapeutics' future performance.
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Rating Raised to "Strong-Buy" at HC Wainwright
HC Wainwright has upgraded Monte Rosa Therapeutics (NASDAQ:GLUE) to a "strong-buy" rating. Despite this upgrade, GLUE shares recently fell 5.6% to $11.26, significantly below their 52-week high, and the company missed quarterly earnings and revenue estimates. The upgrade follows positive Phase 1 results for MRT-8102, showing sustained protein degradation and improved disease biomarkers without major safety concerns, though Phase 2 trials are needed to confirm clinical benefits.
Monte Rosa’s MRT-8102 shows NLRP3 inflammasome activity normalization in Phase 1 study
Monte Rosa Therapeutics announced positive Phase 1 data for its oral molecular glue degrader, MRT-8102, which showed normalization of key pathogenic drivers of atherosclerotic cardiovascular disease in obese participants. The drug targets NEK7, crucial for NLRP3 inflammasome assembly, and demonstrated significant NEK7 degradation and reductions in inflammatory markers without serious adverse events. This promising result paves the way for multiple planned Phase 2 trials for conditions like gout, coronary artery disease, and hidradenitis suppurativa.
Monte Rosa Therapeutics Shares Surge Premarket - Monte Rosa Therapeutics (NASDAQ:GLUE)
Monte Rosa Therapeutics (NASDAQ:GLUE) shares surged over 20% in pre-market trading, driven by anticipation of expanded Phase 1 data for its experimental cardiovascular drug, MRT-8102. The biotech company is set to host a conference call to discuss results from the GFORCE-1 Phase 1 study, which evaluates MRT-8102 as a NEK7-directed molecular glue degrader for patients with elevated cardiovascular disease risk. Investors are keen to see the safety and activity data from multiple dose levels, as well as pioneering data on the drug's modulation of atherosclerotic cardiovascular disease drivers.
Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease
Monte Rosa Therapeutics announced positive Phase 1 trial results for its inflammatory disease drug candidate MRT-8102, which demonstrated significant reductions in inflammatory biomarkers related to cardiovascular disease. The company plans to advance MRT-8102 into three Phase 2 studies for gout, stable coronary artery disease, and hidradenitis suppurativa, with initial data for the gout study expected in late 2027. Despite the positive news, shares of Monte Rosa Therapeutics (NASDAQ: GLUE) were down on the day of the announcement.
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
Monte Rosa Therapeutics announced positive results from its GFORCE-1 Phase 1 study for MRT-8102, a NEK7-directed molecular glue degrader. The study demonstrated that MRT-8102 normalized key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) in obese subjects with elevated CVD risk, showing robust NEK7 degradation and reduction of inflammatory biomarkers. Based on these findings, the company plans to advance MRT-8102 into Phase 2 trials for coronary artery disease, gout, and hidradenitis suppurativa.
Monte Rosa Therapeutics Announces Positive Phase 1 Results for MRT-8102 in GFORCE-1 Trial
Monte Rosa Therapeutics has announced positive Phase 1 results for its drug MRT-8102 in the GFORCE-1 trial, which is designed to treat inflammatory diseases. The study demonstrated significant NEK7 degradation and a reduction in lipoprotein(a) among obese participants, with no serious adverse events reported. Following these promising results, the company plans to advance MRT-8102 into three Phase 2 trials for coronary artery disease, gout, and hidradenitis suppurativa.
An experimental drug brought several heart-disease markers to levels seen in healthy volunteers
Monte Rosa Therapeutics announced positive Phase 1 results for its experimental drug MRT-8102, showing significant reductions in key inflammatory and cardiovascular disease markers in obese subjects with elevated CVD risk. The drug normalized several pathogenic drivers of ASCVD to levels comparable to healthy volunteers, with no serious adverse events. Monte Rosa plans to advance MRT-8102 into Phase 2 studies for coronary artery disease, gout, and hidradenitis suppurativa.
HC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with Buy rating, $25 price target
HC Wainwright & Co. initiated coverage on Monte Rosa Therapeutics (GLUE) with a Buy rating and a $25 price target, suggesting a 109.6% upside. The analyst note highlighted strong early clinical data for MRT-8102, which showed an 85% median reduction in hsCRP levels, and significant partnerships with major pharmaceutical companies like Novartis, validating its QuEEN platform. These factors contribute to investor confidence and enhance the market potential of Monte Rosa's therapeutic candidates.
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
Monte Rosa Therapeutics announced positive results from its GFORCE-1 Phase 1 study for MRT-8102, a molecular glue degrader targeting NEK7, showing normalization of key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) in obese subjects with elevated CVD risk. The study demonstrated robust NEK7 degradation, significant reductions in inflammatory biomarkers, and a favorable safety profile, paving the way for planned Phase 2 trials in coronary artery disease, gout, and hidradenitis suppurativa. The company believes MRT-8102's mechanism of action, targeting NEK7 at the top of the NLRP3 signaling cascade, offers a differentiated approach to treating NLRP3/IL-1-driven inflammatory diseases.
GLUE - Phase 2 Degrader Pipeline And Long Cash Runway Will Support Future Clinical Upside
Monte Rosa Therapeutics (GLUE) is positioned for future growth with multiple Phase 2 trials for its molecular glue degrader platform in cardiovascular, immunology, and oncology, supported by a strong cash runway extending into 2029. Key programs like MRT-8102 are entering advanced trials for conditions such as coronary artery disease and gout, with potential for significant clinical and financial upside. Analysts view the company as undervalued, projecting substantial revenue growth but also highlighting risks related to trial delays and financial performance deviations from expectations.
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history
Monte Rosa Therapeutics, Inc. (GLUE) is a clinical-stage biotechnology company focused on developing novel small molecule precision medicines, including molecular glue degraders (MGDs) for various diseases like cancer, autoimmune, and inflammatory conditions. The article provides detailed financial data, stock performance metrics, analyst ratings, and company overview, indicating a current stock price of $11.26 with a target estimate of $28.00. The company's pipeline includes MRT-2359, MRT-6160, and MRT-8102, and it has strategic collaborations with F. Hoffmann-La Roche Ltd. and Novartis.
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
Monte Rosa Therapeutics announced it will host a conference call and webcast on October 1st to present results from its GFORCE-1 Phase 1 study of MRT-8102. The presentation will cover safety and activity data for MRT-8102 in subjects with elevated cardiovascular disease risk, highlighting its potential to modulate pathogenic drivers of atherosclerotic cardiovascular disease. The webcast will be available on Monte Rosa's website.
Monte Rosa to Present MRT-8102 Phase 1 Data Oct. 1 | GLUE Stock News
Monte Rosa Therapeutics (GLUE) announced it will present results from its MRT-8102 GFORCE-1 Phase 1 study via webcast on October 1, 2026, at 8:00 a.m. ET. The presentation will detail safety and activity data for MRT-8102 across various dose levels after four weeks of treatment in subjects with elevated cardiovascular disease risk, including its effects on atherosclerotic cardiovascular disease drivers. This comes after previous interim results showed reductions in hsCRP and NEK7 degradation, and the stock saw a significant positive movement after the news.
Monte Rosa Therapeutics, Inc. $GLUE Shares Newly Acquired by Bank of America Corp DE
Bank of America Corp DE has acquired 254,561 shares of Monte Rosa Therapeutics (NASDAQ:GLUE) worth approximately $6.16 million, representing a 0.30% stake in the company. Other institutional investors have also increased their holdings, with institutional investors and hedge funds now owning nearly 80% of the company. Despite Monte Rosa Therapeutics missing its Q2 earnings and revenue estimates, analysts maintain a "Moderate Buy" rating with an average price target of $28.50.
(GLUE) Movement Within Algorithmic Entry Frameworks
This article from Stock Traders Daily's Quantitative Research Desk analyzes Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) using algorithmic entry frameworks. It highlights weak near- and mid-term sentiment, posing a challenge to a potentially strong long-term outlook. The analysis provides specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels based on AI-generated signals and multi-timeframe analysis.